Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections. On April 22, 2018, Merck announced that the company presented the results of RESTORE-IMI 1 study at the 28th European Congress of Clinical Microbiology and Infectious Diseases (or ECCMID) in Spain.